Spyre Therapeutics to Participate in Upcoming Investor Conference

WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinicalstage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit. Details of the fir ...